NCT02061540View on ClinicalTrials.gov

Open Label Study to Evaluate Safety and Efficacy of LUM001 in Patients With Primary Sclerosing Cholangitis

PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

February 29, 2016

Study Completion Date

February 29, 2016

Conditions
Primary Sclerosing Cholangitis (PSC)
Interventions
DRUG

LUM001

LUM001 oral dose

Trial Locations (9)

27710

Duke University, Durham

33136

University of Miami, Miami

80045

University of Colorado, Aurora

92037

Scripps Clinic, La Jolla

95817

University of California at Davis, Sacramento

T2N 4Z6

University of Calgary Liver Unit, Calgary

M5T 2S8

University Health Network, Toronto Western Hospital, Toronto

B15 2TT

University of Birmingham, Birmingham

NW3 2QG

Royal Free Hospital, London

Sponsors
All Listed Sponsors
lead

Mirum Pharmaceuticals, Inc.

INDUSTRY